Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Evaluation of Fraction Unbound Across Seven Tissues of Five Species.

Ryu S, Tess D, Chang G, Keefer C, Burchett W, Steeno GS, Novak JJ, Patel R, Atkinson K, Riccardi K, Di L.

J Pharm Sci. 2019 Nov 5. pii: S0022-3549(19)30732-4. doi: 10.1016/j.xphs.2019.10.060. [Epub ahead of print]

PMID:
31704191
2.

Quantitative systems toxicology (QST) reproduces species differences in PF-04895162 liver safety due to combined mitochondrial and bile acid toxicity.

Generaux G, Lakhani VV, Yang Y, Nadanaciva S, Qiu L, Riccardi K, Di L, Howell BA, Siler SQ, Watkins PB, Barton HA, Aleo MD, Shoda LKM.

Pharmacol Res Perspect. 2019 Oct 9;7(6):e00523. doi: 10.1002/prp2.523. eCollection 2019 Dec.

3.

Applying Two Orthogonal Methods to Assess Accuracy of Plasma Protein Binding Measurements for Highly Bound Compounds.

Ryu S, Riccardi K, Patel R, Zueva L, Burchett W, Di L.

J Pharm Sci. 2019 Nov;108(11):3745-3749. doi: 10.1016/j.xphs.2019.08.004. Epub 2019 Aug 13.

PMID:
31419399
4.

A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes.

Riccardi KA, Tess DA, Lin J, Patel R, Ryu S, Atkinson K, Di L, Li R.

Drug Metab Dispos. 2019 May;47(5):484-492. doi: 10.1124/dmd.118.085639. Epub 2019 Feb 20.

PMID:
30787098
5.

6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to β-Estradiol.

Lapham K, Lin J, Novak J, Orozco C, Niosi M, Di L, Goosen TC, Ryu S, Riccardi K, Eng H, Cameron KO, Kalgutkar AS.

Drug Metab Dispos. 2018 Dec;46(12):1836-1846. doi: 10.1124/dmd.118.083709. Epub 2018 Sep 7.

PMID:
30194276
6.

Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines.

Riccardi K, Ryu S, Lin J, Yates P, Tess D, Li R, Singh D, Holder BR, Kapinos B, Chang G, Di L.

Drug Metab Dispos. 2018 Apr;46(4):415-421. doi: 10.1124/dmd.117.079152. Epub 2018 Feb 2.

PMID:
29437874
7.

A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects.

Li R, Niosi M, Johnson N, Tess DA, Kimoto E, Lin J, Yang X, Riccardi KA, Ryu S, El-Kattan AF, Maurer TS, Tremaine LM, Di L.

Drug Metab Dispos. 2018 Apr;46(4):346-356. doi: 10.1124/dmd.117.078790. Epub 2018 Jan 12. Erratum in: Drug Metab Dispos. 2018 Apr;46(4):483. Drug Metab Dispos. 2019 Mar;47(3):269.

PMID:
29330218
8.

Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes.

Riccardi K, Lin J, Li Z, Niosi M, Ryu S, Hua W, Atkinson K, Kosa RE, Litchfield J, Di L.

Drug Metab Dispos. 2017 May;45(5):576-580. doi: 10.1124/dmd.116.074575. Epub 2017 Mar 3.

PMID:
28258068
9.

An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation.

Chang C, Yang X, Fahmi OA, Riccardi KA, Di L, Obach RS.

Xenobiotica. 2017 Aug;47(8):673-681. doi: 10.1080/00498254.2016.1222640. Epub 2016 Sep 5.

PMID:
27595796
10.

Determination of Unbound Partition Coefficient and in Vitro-in Vivo Extrapolation for SLC13A Transporter-Mediated Uptake.

Riccardi K, Li Z, Brown JA, Gorgoglione MF, Niosi M, Gosset J, Huard K, Erion DM, Di L.

Drug Metab Dispos. 2016 Oct;44(10):1633-42. doi: 10.1124/dmd.116.071837. Epub 2016 Jul 14.

PMID:
27417179
11.

Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5).

Huard K, Brown J, Jones JC, Cabral S, Futatsugi K, Gorgoglione M, Lanba A, Vera NB, Zhu Y, Yan Q, Zhou Y, Vernochet C, Riccardi K, Wolford A, Pirman D, Niosi M, Aspnes G, Herr M, Genung NE, Magee TV, Uccello DP, Loria P, Di L, Gosset JR, Hepworth D, Rolph T, Pfefferkorn JA, Erion DM.

Sci Rep. 2015 Dec 1;5:17391. doi: 10.1038/srep17391.

12.

Systematic Evaluation of Bioorthogonal Reactions in Live Cells with Clickable HaloTag Ligands: Implications for Intracellular Imaging.

Murrey HE, Judkins JC, Am Ende CW, Ballard TE, Fang Y, Riccardi K, Di L, Guilmette ER, Schwartz JW, Fox JM, Johnson DS.

J Am Chem Soc. 2015 Sep 9;137(35):11461-75. doi: 10.1021/jacs.5b06847. Epub 2015 Aug 31.

13.

Plasma Protein Binding of Challenging Compounds.

Riccardi K, Cawley S, Yates PD, Chang C, Funk C, Niosi M, Lin J, Di L.

J Pharm Sci. 2015 Aug;104(8):2627-36. doi: 10.1002/jps.24506. Epub 2015 Jun 2.

PMID:
26037784
14.

Dynamic cell culture on calcium phosphate microcarriers for bone tissue engineering applications.

Perez RA, Riccardi K, Altankov G, Ginebra MP.

J Tissue Eng. 2014 Jul 18;5:2041731414543965. doi: 10.1177/2041731414543965. eCollection 2014.

15.

A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling.

Li R, Barton HA, Yates PD, Ghosh A, Wolford AC, Riccardi KA, Maurer TS.

J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):197-209. doi: 10.1007/s10928-014-9357-1. Epub 2014 Apr 10.

PMID:
24718648
16.

Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.

Wang T, Yang Z, Zhang Z, Gong YF, Riccardi KA, Lin PF, Parker DD, Rahematpura S, Mathew M, Zheng M, Meanwell NA, Kadow JF, Bender JA.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):213-7. doi: 10.1016/j.bmcl.2012.10.120. Epub 2012 Nov 7.

PMID:
23200254
17.

Inhibitors of HIV-1 attachment. Part 7: indole-7-carboxamides as potent and orally bioavailable antiviral agents.

Yeung KS, Qiu Z, Xue Q, Fang H, Yang Z, Zadjura L, D'Arienzo CJ, Eggers BJ, Riccardi K, Shi PY, Gong YF, Browning MR, Gao Q, Hansel S, Santone K, Lin PF, Meanwell NA, Kadow JF.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):198-202. doi: 10.1016/j.bmcl.2012.10.115. Epub 2012 Nov 6.

PMID:
23200252
18.

Inhibitors of HIV-1 attachment. Part 8: the effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors.

Yeung KS, Qiu Z, Yin Z, Trehan A, Fang H, Pearce B, Yang Z, Zadjura L, D'Arienzo CJ, Riccardi K, Shi PY, Spicer TP, Gong YF, Browning MR, Hansel S, Santone K, Barker J, Coulter T, Lin PF, Meanwell NA, Kadow JF.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):203-8. doi: 10.1016/j.bmcl.2012.10.117. Epub 2012 Nov 5.

PMID:
23200249
19.

Inhibitors of HIV-1 attachment. Part 9: an assessment of oral prodrug approaches to improve the plasma exposure of a tetrazole-containing derivative.

Yeung KS, Qiu Z, Yang Z, Zadjura L, D'Arienzo CJ, Browning MR, Hansel S, Huang XS, Eggers BJ, Riccardi K, Lin PF, Meanwell NA, Kadow JF.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):209-12. doi: 10.1016/j.bmcl.2012.10.125. Epub 2012 Nov 7.

PMID:
23200244
20.

Phenotypical characterization and adhesin identification in Escherichia coli strains isolated from dogs with urinary tract infections.

Maluta RP, Stella AE, Riccardi K, Rigobelo EC, Marin JM, Carvalho MB, de Ávila FA.

Braz J Microbiol. 2012 Jan;43(1):375-81. doi: 10.1590/S1517-838220120001000045. Epub 2012 Jun 1.

21.

Metabolism-guided design of short-acting calcium-sensing receptor antagonists.

Southers JA, Bauman JN, Price DA, Humphries PS, Balan G, Sagal JF, Maurer TS, Zhang Y, Oliver R, Herr M, Healy DR, Li M, Kapinos B, Fate GD, Riccardi KA, Paralkar VM, Brown TA, Kalgutkar AS.

ACS Med Chem Lett. 2010 May 13;1(5):219-23. doi: 10.1021/ml100058w. eCollection 2010 Aug 12.

22.

Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists.

Didiuk MT, Griffith DA, Benbow JW, Liu KK, Walker DP, Bi FC, Morris J, Guzman-Perez A, Gao H, Bechle BM, Kelley RM, Yang X, Dirico K, Ahmed S, Hungerford W, DiBrinno J, Zawistoski MP, Bagley SW, Li J, Zeng Y, Santucci S, Oliver R, Corbett M, Olson T, Chen C, Li M, Paralkar VM, Riccardi KA, Healy DR, Kalgutkar AS, Maurer TS, Nguyen HT, Frederick KS.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4555-9. doi: 10.1016/j.bmcl.2009.07.004. Epub 2009 Jul 8.

PMID:
19625189
23.

Effects of gestational age on prostaglandin EP receptor expression and functional involvement during in vitro contraction of the guinea pig uterus.

Terry KK, Lebel WS, Riccardi KA, Grasser WA, Thompson DD, Paralkar VM.

Prostaglandins Leukot Essent Fatty Acids. 2008 Jan;78(1):3-10. Epub 2007 Nov 26.

PMID:
18036799
24.

BMP-6 exerts its osteoinductive effect through activation of IGF-I and EGF pathways.

Grasser WA, Orlic I, Borovecki F, Riccardi KA, Simic P, Vukicevic S, Paralkar VM.

Int Orthop. 2007 Dec;31(6):759-65. Epub 2007 Jul 19.

25.

Prostaglandin E2 receptor subtype EP-2 is not involved in the induction of non-pregnant guinea pig uterine contractions associated with terminal pregnancy.

Lebel W, Riccardi K, Grasser WA, Terry K, Thompson D, Paralkar VM.

Prostaglandins Leukot Essent Fatty Acids. 2004 Dec;71(6):399-404.

PMID:
15519499
26.

Emergency preparedness: online resources for hospital healthcare and security professionals.

Riccardi K.

J Healthc Prot Manage. 2004 Summer;20(2):49-54.

PMID:
15457918
27.

The RAFFT as a screening tool for adult substance use disorders.

Bastiaens L, Riccardi K, Sakhrani D.

Am J Drug Alcohol Abuse. 2002 Nov;28(4):681-91.

PMID:
12492264
28.

Security planning for the hospital library: protecting your information assets.

Riccardi K.

J Healthc Prot Manage. 2002 Summer;18(2):94-8.

PMID:
12371251
29.

Including Internet insurance as part of a hospital computer network security plan.

Riccardi K.

J Healthc Prot Manage. 2002 Winter;18(1):119-22.

PMID:
11951384
30.

Macular pigment optical density in a midwestern sample.

Ciulla TA, Curran-Celantano J, Cooper DA, Hammond BR Jr, Danis RP, Pratt LM, Riccardi KA, Filloon TG.

Ophthalmology. 2001 Apr;108(4):730-7.

PMID:
11297490
31.

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF.

Antimicrob Agents Chemother. 2000 Aug;44(8):2093-9.

32.

Effects of olestra and sorbitol consumption on objective measures of diarrhea: impact of stool viscosity on common gastrointestinal symptoms.

McRorie J, Zorich N, Riccardi K, Bishop L, Filloon T, Wason S, Giannella R.

Regul Toxicol Pharmacol. 2000 Feb;31(1):59-67.

PMID:
10715225
33.

Olestra consumption is not associated with macular pigment optical density in a cross-sectional volunteer sample in Indianapolis.

Cooper DA, Curran-Celentano J, Ciulla TA, Hammond BR Jr, Danis RB, Pratt LM, Riccardi KA, Filloon TG.

J Nutr. 2000 Mar;130(3):642-7.

PMID:
10702598
34.

Follow-up to the study: A randomized, double-blind, placebo-controlled consumer rechallenge test of Olean salted snacks.

Zorich NL, Biedermann D, Riccardi KA, Bishop LJ, Filloon TG.

Regul Toxicol Pharmacol. 1998 Feb;27(1 Pt 1):2. No abstract available.

PMID:
9629591
35.

Follow-Up to the study: A randomized, double-blind, placebo-controlled consumer rechallenge test of olean salted snacks

Zorich NL, Biedermann D, Riccardi KA, Bishop LJ, Filloon TG.

Regul Toxicol Pharmacol. 1998 Feb;27(1 Pt 2):2.

PMID:
9618318
36.

Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy.

Deminie CA, Bechtold CM, Riccardi K, Rose RE, Samanta H, Lin PF, Colonno RJ.

AIDS. 1998 Jan 1;12(1):110-2. No abstract available.

PMID:
9456262
37.

Randomized, double-blind, placebo-controlled, consumer rechallenge test of Olean salted snacks.

Zorich NL, Biedermann D, Riccardi KA, Bishop LJ, Filloon TG.

Regul Toxicol Pharmacol. 1997 Oct;26(2):200-9.

PMID:
9356283
38.

Olestra ingestion and dietary fat absorption in humans.

Daher GC, Cooper DA, Zorich NL, King D, Riccardi KA, Peters JC.

J Nutr. 1997 Aug;127(8 Suppl):1694S-1698S. doi: 10.1093/jn/127.8.1694S.

PMID:
9237964
39.

Olestra ingestion and retinyl palmitate absorption in humans.

Daher GC, Cooper DA, Zorich NL, King D, Riccardi KA, Peters JC.

J Nutr. 1997 Aug;127(8 Suppl):1686S-1693S. doi: 10.1093/jn/127.8.1686S.

PMID:
9237963
40.

Olestra dose response on fat-soluble and water-soluble nutrients in humans.

Schlagheck TG, Riccardi KA, Zorich NL, Torri SA, Dugan LD, Peters JC.

J Nutr. 1997 Aug;127(8 Suppl):1646S-1665S. doi: 10.1093/jn/127.8.1646S.

PMID:
9237961
41.

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.

Lin PF, Samanta H, Bechtold CM, Deminie CA, Patick AK, Alam M, Riccardi K, Rose RE, White RJ, Colonno RJ.

Antimicrob Agents Chemother. 1996 Jan;40(1):133-8.

42.

A retrospective cohort study of cancer incidence among New York State Farm Bureau members.

Stark AD, Chang HG, Fitzgerald EF, Riccardi K, Stone RR.

Arch Environ Health. 1990 May-Jun;45(3):155-62.

PMID:
2386420
43.

A retrospective cohort study of mortality among New York State Farm Bureau members.

Stark AD, Chang HG, Fitzgerald EF, Riccardi K, Stone RR.

Arch Environ Health. 1987 Jul-Aug;42(4):204-12.

PMID:
3662607
44.

Epidemiologic patterns of nasal cancer in New York state.

Ulitsky GT, Shalat SL, Riccardi K, Vianna NJ.

J Occup Med. 1981 Sep;23(9):632-4. No abstract available.

PMID:
7277053

Supplemental Content

Loading ...
Support Center